Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

被引：0
|
作者：
Sara M. Tolaney
Hovav Nechushtan
Ilan-Gil Ron
Patrick Schöffski
Ahmad Awada
Chris A. Yasenchak
A. Douglas Laird
Bridget O’Keeffe
Geoffrey I. Shapiro
Eric P. Winer
机构：
[1] Dana-Farber Cancer Institute,Department of Medical Oncology, Breast Oncology Center
[2] Brigham and Women’s Hospital,Department of Medicine
[3] Hadassah Hebrew University Medical Center,Oncology Department
[4] Tel Aviv University,Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine
[5] KU Leuven,Department of General Medical Oncology, Leuven Cancer Institute
[6] Universite Libre de Bruxelles,Medical Oncology, Institut Jules Bordet
[7] Willamette Valley Cancer Institute,undefined
[8] RiverBend Pavilion,undefined
[9] Exelixis,undefined
来源：
Breast Cancer Research and Treatment | 2016年 / 160卷
关键词：
Metastatic breast cancer; Cabozantinib; Vascular endothelial growth factor receptor; Progression-free survival; Overall survival; Tumor response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：305 / 312
页数：7
相关论文
共 50 条
  • [1] Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
    Tolaney, Sara M.
    Nechushtan, Hovav
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Chris A.
    Laird, A. Douglas
    O'Keeffe, Bridget
    Shapiro, Geoffrey I.
    Winer, Eric P.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (02) : 305 - 312
  • [2] Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
    Kelley, R. K.
    Verslype, C.
    Cohn, A. L.
    Yang, T. -S.
    Su, W. -C.
    Burris, H.
    Braiteh, F.
    Vogelzang, N.
    Spira, A.
    Foster, P.
    Lee, Y.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 528 - 534
  • [3] Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma
    Hellerstedt, Beth A.
    Vogelzang, Nicholas J.
    Kluger, Harriet M.
    Yasenchak, Christopher A.
    Aftab, Dana T.
    Ramies, David A.
    Gordon, Michael S.
    Lara, Primo, Jr.
    CLINICAL LUNG CANCER, 2019, 20 (02) : 74 - +
  • [4] Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
    Ratain, Mark J.
    Eisen, Tim
    Stadler, Walter M.
    Flaherty, Keith T.
    Kaye, Stan B.
    Rosner, Gary L.
    Gore, Martin
    Desai, Apurva A.
    Patnaik, Amita
    Xiong, Henry Q.
    Rowinsky, Lric
    Abbruzzese, James L.
    Xia, Chenghua
    Simantov, Ronit
    Schwartz, Brian
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2505 - 2512
  • [5] Abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study
    Michelson, D
    Onawola, R
    Beasley, C
    BIOLOGICAL PSYCHIATRY, 1997, 41 : 332 - 332
  • [6] Abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study
    Michelson, D
    Onawola, R
    Beasley, C
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 556 - 556
  • [7] Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)
    Winer, Eric P.
    Tolaney, Sara
    Nechushtan, Hovav
    Berger, Raanan
    Kurzrock, Razelle
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Christopher A.
    Burris, Howard A.
    Ramies, David A.
    Rafferty, Teresa
    Shen, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT)
    Daud, Adil
    Kluger, Harriet M.
    Edelman, Gerald
    Gordon, Michael S.
    Schimmoller, Frauke
    Weitzman, Aaron
    Samuel, Thomas A.
    Moussa, Ali H.
    Flaherty, Keith
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study
    Zajecka, J
    Fawcett, J
    Amsterdam, J
    Quitkin, F
    Reimherr, F
    Rosenbaum, J
    Michelson, D
    Beasley, C
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) : 193 - 197
  • [10] Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial
    Tolaney, S. M.
    Nechushtan, H.
    Berger, R.
    Kurzrock, R.
    Ron, I. G.
    Schoffski, P.
    Awada, A.
    Yasenchak, C. A.
    Burris, H. A.
    Ramies, D. A.
    Shen, X.
    Winer, E. P.
    CANCER RESEARCH, 2011, 71
12345